GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » FOXO Technologies Inc (AMEX:FOXO) » Definitions » Loans Receivable

FOXO Technologies (FOXO Technologies) Loans Receivable : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is FOXO Technologies Loans Receivable?

FOXO Technologies's Loans Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.


FOXO Technologies Loans Receivable Historical Data

The historical data trend for FOXO Technologies's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FOXO Technologies Loans Receivable Chart

FOXO Technologies Annual Data
Trend Dec20 Dec21 Dec22
Loans Receivable
- - -

FOXO Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FOXO Technologies Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


FOXO Technologies Loans Receivable Related Terms

Thank you for viewing the detailed overview of FOXO Technologies's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


FOXO Technologies (FOXO Technologies) Business Description

Traded in Other Exchanges
N/A
Address
729 Washington Avenue N, Suite 600, Minneapolis, MN, USA, 55401
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging.
Executives
Martin Christopher Ward officer: Interim CFO CHALKSTREAM, KINGS SOMBORNE, STOCKBRIDGE X0 S020 6NZ
Mark Brian White director, officer: Interim CEO IMMEUBLE MILA, CHAMPERY V8 1874
Dowling Vincent J. Jr 10 percent owner 54 LEDYARD, WEST HARTFORD CT 06117
Gwg Holdings, Inc. 10 percent owner 325 N. ST. PAUL STREET, SUITE 2650, DALLAS TX 75201
Taylor Fay officer: Chief Operating Officer 729 N. WASHINGTON AVE, SUITE 600, MINNEAPOLIS MN 55401
Jon Sabes director, 10 percent owner, officer: CEO, Chairman 701 NORTH THIRD STREET, MINNEAPOLIS MN 55401
Bret Barnes director 220 SOUTH SIXTH STREET, MINNEAPOLIS MN 55402
Brian Chen officer: Chief Science Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Erin Sharoni officer: Chief Product Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Michael Will officer: General Counsel 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Tyler Danielson officer: Chief Technology Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Murdoc Khaleghi director 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Robert Potashnick officer: Chief Financial Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul Britton Newhouse director ONE CITY CENTRE, 1021 MAIN STREET SUITE 1960, HOUSTON TX 77002

FOXO Technologies (FOXO Technologies) Headlines